Strategic Partnerships Potential sales opportunity with Provepharm Sas following their US partnership announcement, signaling a channel for expanding injectable and generic product distribution and co-development with Sagent.

Ophthalmic Growth Recent Travoprost Ophthalmic Solution launch provides a doorway to expand and cross-sell into ophthalmic injectable and topical pipelines, including packaging configurations.

Acquisition and Asset Integration Historical asset acquisitions (Athenex assets in 2023, Omega Laboratories in 2014) indicate a pattern of growth through strategic acquisitions, suggesting sales opportunities in integration services, fill-finish capacity, and regulatory support.

Manufacturing Footprint Facility-based operations with past headcount adjustments; opportunities exist to offer scalable manufacturing services, sterile fill/finish, and supply chain optimization to stabilize production capacity.

Recall and Compliance Past quality/sterility recall issues in injectable levetiracetam highlight a need for robust sterile processing, quality assurance, and risk mitigation solutions that can be offered as preventative programs or validation services.